CDK4/6 Inhibitors in Breast Cancer: Clinical Applications, Translational Insights, and Future Directions
Cancers · 23.07.2026 · 18 (15) · 2376
DOI: 10.3390/cancers18152376 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 23.07.2026. Verfasst von Mengying Guan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Yangpu Hospital, School of Medicine, Tongji University, Shanghai 200090, China. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Project of Shanghai Municipal Health Commission, Climb Plan of Tongji University Affiliated Yangpu Hospital, Project of College-level Key Discipline of Yangpu Hospital Affiliated to Tongji University.
Abstract (Originalsprache)
Cyclin-dependent kinase 4/6 inhibitors have fundamentally changed the management of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. However, these drugs are not interchangeable and the field is moving away from the notion of a uniform “class effect.” In early breast cancer, adjuvant abemaciclib and ribociclib improve invasive disease-free survival in patients at a high risk of recurrence, whereas palbociclib does not. This difference likely stems from agent-specific pharmacological profiles, differences in trial design, and patient selection, rather than simply dosing nuances. In metastatic breast cancer, all three agents prolong progression-free survival when combined with endocrine therapy, but only ribociclib and potentially abemaciclib have shown an overall survival advantage. In addition, resistance remains a major obstacle in clinical practice. We propose that resistance mechanisms can be meaningfully grouped into two categories: target-driven (e.g., RB1 loss, CDK6 amplification) and bypass-driven (e.g., ESR1 mutations, PI3K/AKT pathway activation, APOBEC3-mediated mutagenesis). Distinguishing between these classes helps in the design of rational sequencing algorithms and combinatorial regimens. Emerging strategies, such as next-generation protein degraders, oral selective estrogen receptor degraders, antibody–drug conjugates, and inhibition of autophagy, are promising methods for overcoming resistance. Moving forward, the greatest need in breast cancer treatment will be not simply developing additional agents but using current therapies more intelligently by refining biomarker-guided patient selection, tailoring treatment duration, and ensuring broad global access.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast Surgery, Yangpu Hospital, School of Medicine, Tongji University, Shanghai 200090, China.
- Department of Pathology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai 200090, China.
ORCID-Profile: Mengying Guan
Förderung
- Project of Shanghai Municipal Health Commission
- Climb Plan of Tongji University Affiliated Yangpu Hospital
- Project of College-level Key Discipline of Yangpu Hospital Affiliated to Tongji University
Zitieren
APA
Guan, M., & Hao, H. (2026). CDK4/6 Inhibitors in Breast Cancer: Clinical Applications, Translational Insights, and Future Directions. Cancers, 18(15), 2376. https://doi.org/10.3390/cancers18152376
Vancouver
Guan M, Hao H. CDK4/6 Inhibitors in Breast Cancer: Clinical Applications, Translational Insights, and Future Directions. Cancers. 2026;18(15):2376. doi:10.3390/cancers18152376
BibTeX
@article{Guan2026,
author = {Guan, Mengying and Hao, Hua},
title = {CDK4/6 Inhibitors in Breast Cancer: Clinical Applications, Translational Insights, and Future Directions},
journal = {Cancers},
year = {2026},
volume = {18},
number = {15},
pages = {2376},
doi = {10.3390/cancers18152376}
}
EUVIMED